REGISTER 03 · THE DOSE RECORD
BPC-157 TB-500 Dosage: What the Studies Administered
Research-context only. Animal doses by body weight, routes, and reconstitution practice — never a human protocol.
BPC-157 TB-500 Dosage in the Research Literature
BPC-157 TB-500 dosage, as a single number for the blend, does not exist in the peer-reviewed literature. There is no validated dose for the combination in any species, and no controlled combination dose-finding study has been published [9]. What exists are doses for each constituent studied separately, almost entirely in animals, plus a packaging convention for commercial vials. This page describes those research doses and routes. It is not a protocol, and nothing here is a human dosing recommendation.
The constituent figures are these. BPC-157 in rodent studies is commonly expressed per body weight, frequently around 10 µg/kg and 10 ng/kg, with gastric-ulcer cytoprotection studied at 400–800 ng/kg in rats [1][14]. Thymosin beta-4 has been given across a wide range, for example 2–18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study, with an optimal modeled near 3.75 mg/kg and 18 mg/kg giving no benefit — higher was not better [14]. Commercial "Wolverine" labeling commonly pairs the two at fixed combined masses per vial (for example ~10 mg + ~10 mg), but that ratio has no dose-finding basis [11]. The sections below lay out the BPC-157 TB-500 dosage in the literature by constituent, route, and handling practice.
Pharmacokinetics and half-life
No validated human pharmacokinetic half-life exists for either constituent at research doses, and none for the blend [14]. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study [14]. Human full-length thymosin beta-4 showed dose-proportional pharmacokinetics with half-life increasing at higher doses, but no specific half-life is established for the TB-500 seven-amino-acid fragment [11][14]. The blend's pharmacokinetics are, accordingly, unknown.
What is the half-life of BPC-157 and TB-500?
No validated human PK half-life exists for either constituent at research doses, and none for the blend [14]. BPC-157's elimination half-life was reported under 30 minutes in a rat/dog PK study; human full-length thymosin beta-4 showed dose-proportional PK, but no half-life is established for the TB-500 heptapeptide [11][14].
Routes, reconstitution, and frequency in research handling
The routes that appear in the literature belong to the constituents, not to a tested blend protocol. The underlying rodent efficacy studies used intraperitoneal dosing predominantly; human single-agent work on full-length thymosin beta-4 and a BPC-157 safety pilot used intravenous routes; and local, topical, and oral routes appear in individual-compound models [1][11]. Subcutaneous and intramuscular are the predominant research-community routes for the blend, but those are not drawn from controlled human efficacy trials [11].
Wolverine Injection: Routes Studied in the Literature
The "Wolverine injection" maps to routes studied for the constituents, not a validated blend route. Rodent efficacy studies used intraperitoneal dosing; intravenous appears in a BPC-157 safety pilot and in human full-length thymosin beta-4 work; subcutaneous and intramuscular are the common research-community routes for the blend but lack controlled-trial backing [1][11].
BPC 157 TB 500 Oral Versus Injectable
BPC-157 is studied as a "stable gastric" peptide with oral/peroral research models, which is why oral blend products are marketed [1]. But no validated oral pharmacokinetics exist for the blend, and most efficacy data for both peptides come from injected routes in animals [11]. Oral versus injectable for the combination is an open question, not a settled one.
BPC-157 TB-500 Blend Dosage Per Day in Research Models
There is no validated per-day dose for the blend in any species [9]. Animal studies dose each peptide separately and by body weight — BPC-157 frequently around 10 µg/kg, thymosin beta-4 across a wide mg/kg range [1][14]. A rat thymosin beta-4 study even found dosing non-monotonic, with 18 mg/kg giving no benefit, which undercuts any fixed daily "more is better" figure [14].
Can You Mix BPC-157 With TB-500 in the Same Syringe?
Community practice reconstitutes the two peptides separately or in a shared vial, but no validated reconstitution protocol exists for the blend, and product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed [11]. Combining two unverified peptides compounds the existing identity caveat around TB-500 (fragment versus full-length thymosin beta-4).
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [11]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed, and no validated reconstitution protocol exists for the blend.
How often should you inject BPC-157 and TB-500?
There is no validated dosing frequency for the blend in humans [9]. Community "loading then maintenance" protocols and fixed-ratio vials (for example 10 mg + 10 mg) have no controlled-trial basis [11]. Research routes (SC/IM/IP) are described for the constituents in animal studies only.
How do you cycle BPC-157 and TB-500?
No validated cycling schedule exists for the blend [9]. Community loading/maintenance cycles have no controlled-trial basis, and a rat embolic-stroke study found thymosin beta-4 dosing non-monotonic (a high 18 mg/kg dose gave no benefit), undermining "more is better" loading rationales [14].